# Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

> **NCT06015568** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 172 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

## Interventions

- **DRUG:** MCLA-129: 1500mg or 2000mg IV Q2W
- **DRUG:** Befotertinib: 75 mg or 100 mg Po QD

## Key facts

- **NCT ID:** NCT06015568
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2028-11-04
- **Final completion:** 2029-07-04
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015568, "Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06015568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*